Axitinib-Pembrolizumab and Adverse Event Management in Patients With Advanced Renal Cell Carcinoma - Takeaways - MDSpire

Axitinib-Pembrolizumab and Adverse Event Management in Patients With Advanced Renal Cell Carcinoma

  • By

  • Neil J. Shah

  • Yaa Ababio

  • Anthony Eccleston

  • Dharanija Rao

  • Scott P. Kelly

  • Jane Chang

  • Sarah Lucht

  • Caleb Paydar

  • Bryce A. Van Doren

  • Emily Bland

  • William John

  • Sarah Giegerich

  • JaLyna Laney

  • Bruce Feinberg

  • Kevin K. Zarrabi

  • May 21, 2026

  • 0 min

Share

  • 1

    Cancer of the kidney and renal pelvis is the seventh most common malignant neoplasm in the US, with 80,980 new cases and 14,510 deaths estimated for 2025.

  • 2

    15%.

  • 3

    which is associated with a lower 5-year survival rate (19.1%) compared with localized (93.3%) or regional (76.4%) disease.

  • 4

    Within RCC, clear cell carcinoma is the most common histologic subtype, comprising 70% to 80% of diagnoses.

  • 5

    April 2019.

Original Source(s)

Axitinib-Pembrolizumab and Adverse Event Management in Patients With Advanced Renal Cell Carcinoma

  • by Neil J. Shah, Yaa Ababio, Anthony Eccleston, Dharanija Rao, Scott P. Kelly, Jane Chang, Sarah Lucht, Caleb Paydar, Bryce A. Van Doren, Emily Bland, William John, Sarah Giegerich, JaLyna Laney, Bruce Feinberg, Kevin K. Zarrabi

  • May 21, 2026

Related Content

Treatment evolution and survival impact of consolidation therapies in mantle cell lymphoma: insights from an Asia-Pacific real-world registry

Artificial intelligence for optimization of immunotherapy: current applications and transformative potential

Emerging applications of artificial intelligence for risk stratification in head and neck cancer: a scoping review